ClinicalTrials.gg
RecruitingNCT04010201Updated Sep 23, 2019

A Registered Cohort Study on Brain Calcification

An observational study in Brain Calcification, sponsored by Wan-Jin Chen. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2019-09-23.

Sponsored by Wan-Jin Chen · Observational

How we know

From the registry’s dates

  • Started Aug 2019; still recruiting 7 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Sex
All
01

Study summary

Brain calcification is a common neuroimaging feature in patients with metabolic, neurological, or developmental disorders, infectious diseases, traumatic or toxic history, as well as in otherwise normal older people. To understand the clinical and genetic characteristics of brain calcification, we establish a cohort of brain calcification to follow up patients with brain calcification.

02

Conditions studied

  • Brain Calcification

Keywords

  • brain calcification
  • natural history
  • genetics
03

In context

Lead sponsor

Wan-Jin Chen is the lead sponsor of 5 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Brain calcification patients who are diagnosed in the First Affiliated Hospital of Fujian Medical University

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with brain calcium deposit(s) based on examinations of CT scans
  • Patients with total calcification score(TCS) greater than the physiological threshold
  • Relatives of brain calcification patients.
  • Unrelated healthy controls
  • Participants or Parent(s)/legal guardian(s) willing and able to complete the process

Exclusion criteria

Exclusion Criteria:

  • Brain calcification caused by specific secondary factors such as infection, poisoning, and trauma
  • Participants declining or unable to comply with trial procedures and visit schedule
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. The incidence of hereditary brain calcification

    Look for the causative gene in the patient with brian calcification

    Time frame: Up to 20 years

07

Study locations

1 of 1 sites recruiting
  • Department of Neurology, First Affiliated Hospital Fujian Medical University
    Fuzhou, Fujian 350005, China
    Recruiting
    • Wan-Jin Chen, PhD · Contactwanjinchen75@fjmu.edu.cn · 86-0591-87982772
    • Wan-Jin Chen, MD,PhD · Principal investigator
    • Ning Wang, MD, PhD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2019 (actual). Primary completion is estimated for Dec 2029, 124 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2019
First posted
Jul 8, 2019
StartActual
Aug 25, 2019
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2079
Last update
Sep 23, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04010201
Lead sponsor
Wan-Jin Chen
Responsible party
Wan-Jin Chen (The Vice-Director for the Department of Neurology, First Affiliated Hospital of Fujian Medical University) — Sponsor-investigator
First posted
Jul 8, 2019
Start date
Aug 25, 2019
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2079 (estimated)
Last update
Sep 23, 2019

Study contacts

Yi Lin, PhD
Contact
linyi7811@163.com
86-0591-87982772
Wan-Jin Chen, PhD
Contact
wanjinchen75@fjmu.edu.cn
86-0591-87982772

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion